10.1039/d1fo02733f Summary Keywords diabetic kidney disease, hydroxyurea, inflammation, apoptosis, s6k Citation Cheng W, Wang C, Ma M and Zhou Y (2025) Hydroxyurea mitigates diabetic kidney disease through mTOR-S6K signaling pathway in STZ-induced diabetic mice
Patients with T2D suffer from various diabetes-related complications
Only a small fraction of employer-sponsored health plans (about 20 percent) cover these medications, leaving millions of patients facing either paying the full cost or forgoing treatment
Obesity , 27 (4), 591-602
For most people, a 1:00 PM session will wear off by bedtime, allowing for a normal sleep cycle
AstraZeneca has deliberately chosen not to directly compete in the GLP-1/GIP receptor agonist space a strategic choice that, while differentiating, leaves it without exposure to the highest-growth peptide market segment (65.8% of the peptide therapy market